SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. purchased 30.48M shares of SATSUMA PHARMACEUTICALS, INC. on the open market
Open‑market purchase worth $27.73M. The strongest form of insider conviction signal.
P · 2 purchases
Filed: 6/8/2023ACC: 0000899243-23-014866
→
10% Owner
Since Jun 2023
+30.48M
Net shares
Net buyer
$27.73M
Total acquired
2
Open market trades
2B · 0S
2
Total transactions
30.48M acquired
Non-Derivative Transactions2
Common Stock
Indirect
Shares
+22.05M
Price / share
$0.91
Trade value
$20.07M
% of position
New position
6/6/2023
0.00→22.05M
Common Stock
Indirect
Shares
+8.42M
Price / share
$0.91
Trade value
$7.67M
% of position
New position
6/8/2023
0.00→8.42M
Total
Net shares
+30.48M
Net value
$27.73M
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Indirect | 6/6/2023 | P · Purchase | +22.05M | $0.91 | $20.07M | New position | 0.00 | 22.05M |
| Common Stock Indirect | 6/8/2023 | P · Purchase | +8.42M | $0.91 | $7.67M | New position | 0.00 | 8.42M |
| Total | +30.48M | $27.73M | ||||||
Derivative Transactions0
No derivative transactions reported
Non-Derivative Holdings (Post-Transaction)2
Common Stock
DirectShares owned2.56M
Common Stock
IndirectShares owned233.33K
Total
2.56M direct·233.33K indirect2.79M
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock | 2.56M | Direct |
| Common Stock | 233.33K | Indirect |
| Total | 2.79M | 2.56M direct·233.33K indirect |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported